Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

Key facts

Sponsor

Kyorin University

Principal Investigator

Motoo Nagane, M.D., Ph.D.

Kyorin University Faculty of Medicine, Department of Neurosurgery

Intervention

Temozolomide(drug)

Enrollment

146 enrolled

Eligibility

20-75 years · All sexes

Timeline

2016 – 2025

Study locations (30)

• Nagoya University Hospital, Nagoya, Aichi-ken, Japan
• Fujita Health University Hospital, Toyoake, Aichi-ken, Japan
• Hirosaki University School of Medicine, Hirosaki, Aomori, Japan
• Ehime University Graduate School of Medicine, Shizukawa, Ehime, Japan
• Kurume University Hospital, Kurume-shi, Fukuoka, Japan
• Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan
• Kobe University Hospital, Kobe, Hyōgo, Japan
• University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan
• Iwate Medical University, Morioka, Iwate, Japan
• Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
• Nagasaki University Hospital, Nagasaki, Nagasaki, Japan
• Kansai Medical University, Hirakata, Osaka, Japan
• Osaka University Graduate School of Medicine, Suita, Osaka, Japan
• Saga University Hospital, Saga, Saga-ken, Japan
• Saitama Medical University International Medical Center, Hidaka, Saitama, Japan
• +15 more locations on ClinicalTrials.gov

Collaborators

Japan Clinical Oncology Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06176066
  PH Sensitive MRI Based Resections of Glioblastoma
  University of California, Los Angeles
• RECRUITINGNCT05864976
  Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
  Washington University School of Medicine
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05685004
  Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
  TVAX Biomedical
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04922723
  Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
  West Virginia University
• RECRUITINGPHASE1NCT05083754
  Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• ACTIVE NOT RECRUITINGPHASE1NCT04968366
  Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
  Beijing Tiantan Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT04574856
  Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
  University of Michigan Rogel Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT04116411
  A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
  Cecilia Soderberg-Naucler

See all trials for Giant cell glioblastoma →